Skip to content

Improving Access to Breast Cancer Screening and Treatment in Nigeria: The Triple Mobile Assessment and Patient Navigation Model

Improving Access to Breast Cancer Screening and Treatment in Nigeria: The Triple Mobile Assessment and Patient Navigation Model

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05321823
Enrollment
4100
Registered
2022-04-11
Start date
2021-12-08
Completion date
2023-10-31
Last updated
2022-04-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

Screening, Treatment, Navigation, Triple Mobile assessment

Brief summary

The goal of this study is to establish a novel community-based breast cancer program to address delayed presentation and lack of access to diagnostic and treatment facilities in South-West Nigeria. It is aimed at evaluating the impact of a novel breast cancer early detection program using triple mobile assessment (innovative handheld iBreast Exam \[iBE\] device, mobile ultrasound, and mobile mammography) and patient navigation program in a Nigerian community.

Detailed description

This study aims to provide screening to asymptomatic women 40-70 years and to provide diagnostic evaluation to women 30-70 years presenting with breast symptoms in a community in South-West Nigeria. The project will use a cluster randomized design with 1 community serving as the intervention arm and another community serving as the control arm. Both communities will receive breast cancer awareness and education but only the intervention community will receive screening, mobile imaging and navigation. Screening with targeted clinical history, Clinical Breast Exam (CBE), and iBE will be performed by trained Community Health Nurses in the intervention community. Women with positive CBE or iBE findings will undergo breast imaging with mobile mammography and portable ultrasound, as well as biopsy when indicated by the Radiologist who visits the community once a month, and receive navigation by the nurses to the point of care. The control population will receive breast cancer awareness without an organized screening, imaging or navigation program. Women presenting to the Primary Health Care Centers in the control community will be referred to the Teaching Hospital as per current standard of care. Record of all breast cancer cases seen in the 2 communities during the study period will be obtained.

Interventions

DEVICEiBreast device

The iBreast (iBE) device is an automated, battery powered, portable device designed to be used by community health nurses as a screening and triage tool. The iBE is designed to be used by a community health worker or lay person after appropriate training. In resource-limited settings, it potentially provides an easily accessible, low-cost method to assess the breast for findings that warrant further evaluation.

OTHERClinical Breast Examination

The standard clinical breast examination (CBE) will be performed by the community health nurses in the selected primary health care centers where patients will present for screening or diagnostic workup in the intervention community

DIAGNOSTIC_TESTBreast ultrasound

Women in the intervention community who have positive iBE and/or CBE findings will be navigated by the community health nurses to have ultrasound with or without ultrasound-guided breast biopsy if indicated by the radiologist using portable ultrasound tablets that will be brought to the intervention community.

DIAGNOSTIC_TESTMammography

Women in the intervention community who have positive iBE and/or CBE findings will be navigated by the community health nurses to have mammography done using a mobile mammography van that will be brought to the intervention community.

Sponsors

Pfizer
CollaboratorINDUSTRY
Obafemi Awolowo University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
NONE

Intervention model description

The study will be carried out in 2 local counties (Local Government Areas) in Osun State, South-West, Nigeria, Ife North Local County and Ife East Local County. Three districts in Ife North Local County with an estimated screening population (women 40-70 years) of 5,800 will be randomly selected to serve as the intervention community, while 2 districts in Ife East Local County with an estimated screening population of 4,500 will be randomly selected to serve as the control community. Both communities will receive awareness and education, but only the intervention community will receive screening and navigation.

Eligibility

Sex/Gender
FEMALE
Age
30 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Asymptomatic women 40 - 70 years * Symptomatic women (with breast-related symptoms) 30 - 70 years

Exclusion criteria

* Male subjects * Women living outside the study locations (Ife East and Ife North districts)

Design outcomes

Primary

MeasureTime frameDescription
Participation rateAfter year 1 of the 2-year study periodPercentage of women screened of the total number of eligible women in each community.
Abnormal call rateAfter year 1 of the 2-year study periodNumber of women with abnormalities detected on iBE and/or CBE requiring further evaluation either by imaging or biopsy out of the total number of women screened.
Breast cancer detection rateAfter year 1 of the 2-year study periodNumber of histologically diagnosed cases of breast cancer per 1,000 screened populations.
Stage at presentationAfter year 1 of the 2-year study periodThe tumour, node and metastasis (TNM) stage among those with histologically confirmed breast cancer.
Timeline from presentation to treatmentAfter year 1 of the 2-year study periodTime interval between presentation for screening in the community and treatment in the tertiary hospital
Retention rateAfter year 2 of the 2-year study periodNumber of women who return for repeat annual screening of the total initial number of women screened.

Countries

Nigeria

Contacts

Primary ContactAdeleye D Omisore, MBBS, M.Sc, FWACS, FMCR
leyeomisore@oauife.edu.ng+234803538004

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026